ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 09/26/23

2023-09-26 15:08:59 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Novartis and Ionis in pact for new cardiovascular therapy AstraZeneca-Ionis deal for eplontersen expands to Latin America S...

- Arrowhead Expands the Reach of RNAi Therapies to Address Diseases in the Lung - Late-Breaking Clinical Data for ARO-RAGE for Treatment of Asthma Demonstrate Deep and Durable Gene Silencing - Promising Preclinical Data Across Multiple Gene Targets Suggest Potentially Broad Applications f...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 18 th Annual BioPharma Conference – September 6, 2023 Type: 1-on-1 Investor Meetings European Respiratory Society (ERS) I...

2023-08-11 11:38:16 ET Summary Arrowhead Pharmaceuticals had a strong financial performance in Q1 2023, a compelling RNAi therapeutic pipeline, and beneficial strategic partnerships. However, the company's recent financial performance in Q2 2023 showed a significant drop in revenu...

2023-08-07 18:35:02 ET Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2023 Earnings Conference Call August 07, 2023 04:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - President & Chief Executive Officer Javier San...

2023-08-07 16:40:39 ET Arrowhead Pharmaceuticals press release ( NASDAQ: ARWR ): Q3 GAAP EPS of -$0.96 misses by $0.37 . Revenue of $15.83M (-51.2% Y/Y) misses by $29.59M . For further details see: Arrowhead Pharmaceuticals GAAP EPS of -$0.96 misses by $0...

Conference Call and Webcast Today, August 7, 2023 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m. ET to discuss the...

2023-07-30 06:20:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Opportunity Fund outperformed the broader market in Q2 2023, with a 16.31% retur...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 third quarter ended June 30, 2023. Webcast and Conference Call and Details Investors ma...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for patients with fac...